O-RAN Announces Certification and Badging Program, Next Generation Research Group, Open RAN Summit, and Results of Spring 2022 PlugFest
30.6.2022 10:33:00 EEST | Business Wire | Press release
Since its beginning in 2018, the O-RAN ALLIANCE’s mission has been transforming Radio Access Networks towards open, intelligent, virtualized and fully interoperable RAN. Now, the O-RAN Ecosystem counts more than 340 companies and institutions from all over the world. O-RAN’s emphasis on openness is reflected in its setup as an open technical organization, according to the WTO criteria, where incumbent as well as emerging industry players or academic institutions can join and contribute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005362/en/
O-RAN ALLIANCE Industry Summit June 2022
The O-RAN ALLIANCE Industry Summit June 2022 concluded on June 29, 2022 and is now available for on-demand replay at our website.
O-RAN Certification and Badging Program in cooperation with Open Test and Integration Centres (OTIC)
O-RAN ALLIANCE has launched its Certification and Badging program. O-RAN certificates state that an equipment or function is conformant to O-RAN specifications, whereas the O-RAN badges confirm interoperability or end-to-end functionality of an O-RAN solution. O-RAN certificates and badges will be issued by the Open Testing and Integration Centers, or OTICs.
The OTICs provide collaborative, open, and impartial working environment to ensure consistency and quality of testing of O-RAN products and solutions. O-RAN ALLIANCE has just approved the 7th OTIC and first one in Americas: Kyrio O-RAN Test and Integration Lab hosted by CableLabs.
See the full list of approved OTICs at our website.
O-RAN next Generations Research Group will focus on future network standards
O-RAN ALLIANCE has formed its next Generations Research Group (nGRG).
“The nGRG will focus on research of open and intelligent RAN principles in 6G and future network standards,” said Chih-Lin I, Co-chair of O-RAN Technical Steering Committee and Chief Scientist, Wireless Technologies, China Mobile Research Institute. “We are seeing very positive uptake on nGRG from the O-RAN ecosystem as well as the academic sphere and we are looking forward to seeing further progress of the research.”
Open RAN Summit @ Fyuz to be held on 25-26 October 2022 in Madrid
O-RAN ALLIANCE is delighted to announce the Open RAN Summit @ Fyuz, powered by the O-RAN ALLIANCE and Telecom Infra Project, which will take place in Madrid on October 25-26, 2022. We welcome TIP as they join us for this combined event.
Designed to bring together stakeholders from across the ecosystem, the Open RAN Summit at Fyuz will deliver the latest from the industry as we drive towards more disaggregated, intelligent, open, and fully interoperable mobile networks. All of that, served in a unique experience combining technology with gastronomy to stir your imagination. Learn more and register at the Fyuz event website.
O-RAN Global PlugFest Spring 2022 concluded at 3 continents with 50 participants
Starting from this year, O-RAN ALLIANCE switches to hosting two global PlugFests per year, to accommodate for ever increasing interest of the diverse O-RAN community to efficiently test and integrate their O-RAN solutions.
O-RAN Global PlugFest Spring 2022 took place at 3 continents with 50 participating companies or institutions, some of which participated at more than one venue.
In North America, the O-RAN ‘PoCFest’ hosted by AT&T and DISH spanned across 4 labs in cooperation with several universities:
- TIP Community Lab at Meta, Menlo Park CA
- POWDER Lab and NSF PAWR SITE with the University of Utah
- COSMOS Lab and NSF PAWR SITE with the Rutgers University, Columbia University, NYU Wireless
- InterOperability Lab at the University of New Hampshire
Activities focused on demonstrations of use cases within the O-RAN Use Cases Detailed Specification version 6.0 & 7.0, as well as use cases that are currently in the process of being specified such as Energy Saving / Energy Efficiency. More than 20 unique O-RAN components were tested for conformance to O-RAN specifications.
The Proof-of-Concept approach also supported the evolution of testbeds across companies and research institutions, which is expected to accelerate the availability of next generation research platforms, consistent with the mission of the recently established nGRG within O-RAN.
In addition to the hosts and labs, participants included Analog Devices, Anritsu, Calnex Solutions, Cisco, Fujitsu, HCL, highstreet technologies, IP Infusion, ITRI, Juniper Networks, Keysight Technologies, META, NSF ARA: Living Wireless Lab, NSF PAWR: AERPAW, NSF PAWR: Colosseum, Rohde & Schwarz, VIAVI Solutions, VMware and Wind River.
In Europe, the O-RAN PlugFest Spring 2022 hosted by Telefonica took place at the European OTIC in Madrid.
Activities focused on testing of open Xhaul transport solutions, including data plane functional and performance testing, as well as synchronization. Testing scenarios were mimicking realistic deployments with diversity of technologies, protocols, and encapsulations, to obtain meaningful insights on the solutions under test. There were three setups with different transport equipment, two instrumentation vendors, and one transceiver manufacturer.
In addition to the host, participants included ADVA Optical Networking, Juniper Networks, Keysight Technologies, Precision Optical Transceivers, Ribbon and VIAVI Solutions.
In Asia, O-RAN PlugFest Spring 2022 hosted by Auray took place at the Auray OTIC and Security Lab.
Divided into 18 test cases, activities focused on verification and validation of applicability of tests in a lab environment, specifically for Open Fronthaul tests, end-to-end tests, and Denial of Service (DoS) and blind exploitation types of security tests.
Performed actions covered a dry run of the O-RAN Certification and Badging, verifying the related processes and procedures.
The PlugFest also included Open RAN Testing and Optimization for Industry IoT – smart scoring methodology for end-to-end service experience based on 3GPP 5G E2E KPIs.
In addition to the host, participants included Alpha Networks, Askey Computer, Calnex Solutions, Foxconn, Institute for Information Industry, Inventec, IP Infusion, ITRI, JPC connectivity, Keysight Technologies, Lions Technology, LITEON, MICAS, NKG, Pegatron, QCT, REIGN Technology, Rohde & Schwarz, Sageran, VIAVI Solutions and WNC.
The O-RAN ALLIANCE is preparing a web announcement and a Virtual Showcase to allow interested public to explore the O-RAN Global PlugFest Spring 2022 in detail – soon to be available at our website.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 340 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005362/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
